NIDA Director, Nora Volkow talks about the need for treatments for stimulant and polysubstance use and overdoses during the 152 Meeting of the National Advisory Council on Drug Abuse

Cambridge, MA | March 2026

https://videocast.nih.gov/watch/73b8cb15-0e86-11f1-9f14-124f0a52e769

During the 152 meeting of the National Advisory Council on Drug Abuse, NIDA Director, Nora Volkow, discusses the challenges to treatment and overdoses, particularly surrounding stimulants and polysubstance use disorder.

Dr. Volkow highlights that there are currently no FDA approved medication for stimulant use disorder, nor is there treatment available for polysubstance use.  She also notes that while opioid deaths are decreasing, stimulant deaths are increasing, equaling out the fatalities by drug class.

About Clear Scientific 

Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland. 

Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body.  Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals. 

About CS-1103 

CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. The Company is initially targeting methamphetamine, fentanyl and cocaine overdose, representing close to 95% of the drug fatalities in the US. Clear Scientific’s pipeline includes indications in central nervous system (CNS), metabolic diseases, amongst others. 

For more information, visit https://www.clearsci.com.